he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信源地址
上一页:引来癫痫发作的原因有哪些
- 2022-05-022013年国际上抗癫痫联合会抗癫痫药使用指南
- 疾病新知:毛囊性白癜风
- Gut:急性COVID-19肠道微生物群综合征患者的动态变化
- 全球干细胞临床试验1000多项,在白癜风领域潜力巨大
- 虽然医学越来越发达,但这四种疾病尚未治愈!别再上当了
- AP&T:使用anti-TNFα治疗自身免疫性疾病的患者会增加患炎症性肠病的几率
- 病例报告:水浴 PUVA 治疗皮下环状肉芽肿
- FDA批准Aptiom用于治疗患者癫痫发作
- 姑息治疗:不是放弃希望,而是积极治疗
- 白癜风症状 有些白斑可以预防白癜风
- FDA警告怀孕期间使用丙戊酸钠药物
- 20130529健康生活视频:李志红讲如何调理上热下
- 美国FDA关于坏死因子阻滞剂、硫唑嘌呤和/或硫唑嘌呤的安全性更新
- 胰高血糖素瘤 胰高血糖素瘤的临床表现是什么?
- LEEP手术知道多少?
- 20120328健康来了:范志红讲芹菜叶的功效和作用
- 如何最有效地去除黑头?
- 自身免疫病也可以免疫治疗
- 雷安平主任:白癜风的诊断依据是什么?
- FDA批准塞尔基因Otezla治疗银屑病性关节炎
- JAMA:阳性结果的文章一定更受关注吗?
- 脑梗死的症状是什么有这些前兆要谨慎
- 解读功能障碍性子宫出血
- 孩子脸上有白斑,肚子里有蛔虫?医生:不是蛔虫斑,可能是癌症
- 四大饮食改善患者病情
- 癫痫猝死:凶手是谁?
- 黑头怎么去?
- 原发癫痫病能救活吗
- 老年人癫痫病的早期症状 临床分类及表现
- 20130712养生:杨红宣讲癫痫病人不会吃什么
- 癫痫病用药材能治好吗 癫痫病应该怎么治疗
- 怎么治癫痫病最合理啊
- 长期酗酒 无需警惕 Marchiafa-Bignami 病
- 怎么才能但他却的发现有癫痫病?
- 癫痫病的早期症状 患有癫痫万不可吃到它(2)
- NeuroImage:纤维球成像可用于癫痫疟疾进展
- 再次出现间歇性癫痫能治好吗
- 治疗癫痫病较为好的方法有哪些
- 放射治疗癫痫病小发作药物
- 回忆神内副较低笔试
- 少年儿童癫痫病因是什么呢